NorthWest Biotherapeutics Inc (NWBO)

[The Danish Dude]

Why ORR did NOT matter in Direct trial phase 1 and why it DOES matter, when restarting it.



Why the Phase 1 DCVax-Direct Trial Results Were Great:

Extended Survival:
Despite the advanced, heavily pre-treated patient population with poor prognosis, the top 20% of patients exceeded 2 years of survival, and the top 30% doubled their expected survival (26.7 months vs. 12.3 months).

Immune Activation Evidence:
The trial showed immune engagement, such as increased PD-L1 expression and T-cell infiltration, indicating DCVax-Direct effectively stimulated an anti-tumor immune response.

Diverse Cancer Types:
Demonstrating feasibility and safety across over a dozen inoperable tumor types highlights the therapy’s broad potential applicability.

Why ORR Did NOT Matter in Phase 1:

Immunotherapy Characteristics:
Immunotherapies like DCVax-Direct often show delayed effects, with benefits measured in survival and immune activation rather than immediate tumor shrinkage.

End-Stage Patients:
The advanced disease stage and prior treatment failures made achieving measurable tumor shrinkage unlikely.

Primary Focus:
Phase 1 trials prioritize safety, feasibility, and signals of durable benefit, which were successfully demonstrated, making ORR irrelevant at this stage.

Why ORR Was NOT Suitable for Phase 1 DCVax-Direct Trial:

Mechanism of Action:
DCVax-Direct works by gradually stimulating the immune system to attack tumors, often resulting in delayed responses rather than immediate tumor shrinkage.

Early Trial Goals:
Phase 1 focused on safety, feasibility (intra-tumoral injection), and survival outcomes, which are more relevant for assessing initial efficacy in heavily pre-treated, end-stage patients.

Patient Population:
The trial involved patients with poor prognosis and highly advanced cancers, where immediate tumor reduction was unlikely.

Why ORR Is Suitable for the Restart of DCVax-Direct:

Combination Therapy:
Combining DCVax-Direct with complementary agents could lead to faster and more measurable tumor shrinkage.

Shorter Timelines:
ORR (tumor shrinkage) can be evaluated within months, aligning with NWBO’s strategy to achieve quicker trial results compared to survival endpoints.

Regulatory and Clinical Appeal:
Demonstrating ORR provides immediate, quantifiable evidence of efficacy, essential for gaining regulatory approval and increasing clinical adoption.

So let's sum up ex, so you don't end up infesting more science articles, with questions making you look stupid, like you did with ATL-DC.

The Phase 1 DCVax-Direct trial endpoint was safety, feasibility, and survival, not ORR, because the focus was on evaluating the therapy's ability to stimulate an immune response in end-stage patients with poor prognosis, where immediate tumor shrinkage was unlikely. making ORR an unsuitable measure at this stage.

The restart trial's endpoint IS tumor shrinkage (ORR) to provide faster, measurable results within months. This shift is due to the inclusion of combination therapies that enhance immediate tumor response, making it a practical and efficient measure compared to survival-focused endpoints in Phase 1, which required years to evaluate.